Join to View Full Profile
170 University of NCTrlr CbChapel Hill, NC 27599
Phone+1 732-236-3903
Dr. Zeidner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014- Johns Hopkins UniversityResidency, Internal Medicine, 2008 - 2011
New York Medical CollegeClass of 2008
Certifications & Licensure
NC State Medical License 2014 - 2025
MD State Medical License 2011 - 2015
American Board of Internal Medicine Medical Oncology
Clinical Trials
- High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Start of enrollment: 2016 Aug 22
- A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS Start of enrollment: 2018 Aug 29
- Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Start of enrollment: 2022 Aug 24
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.Hetty E Carraway, Andrew M Brunner, Catherine E Lai, Marlise R Luskin, Jae Park
Clinical Lymphoma, Myeloma & Leukemia. 2025-08-01 - A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.Eric D Eisenmann, Ronan Swords, Ying Huang, Shelley Orwick, Daelynn Buelow
Cancer Research Communications. 2025-07-01 - Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed-Mutated or-Rearranged AML.Joshua F Zeidner, Tara L Lin, Rina Li Welkie, Emily Curran, Kristin Koenig
Journal of Clinical Oncology. 2025-06-12
Journal Articles
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
Abstracts/Posters
- OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid LeukemiaJoshua F Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)Joshua Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid TumorsJoshua F Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Authored Content
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
Press Mentions
Adding Menin Inhibitor Promising in Certain AML PatientsJune 13th, 2025- Precision Drug Combination Achieves 88% Response in Older Leukemia PatientsJune 13th, 2025
- Rewrite Novel Drug Combination Is Safe and Benefits People with Acute Myeloid Leukemia Who Have a Specific Genetic Profile This News Headline for the Science Magazine PostJune 12th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
